Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

American Society for Clinical Investigation full text link American Society for Clinical Investigation Free PMC article
Full text links

Actions

Review
.2007 Aug;117(8):2051-8.
doi: 10.1172/JCI32278.

ErbB receptors: from oncogenes to targeted cancer therapies

Affiliations
Review

ErbB receptors: from oncogenes to targeted cancer therapies

Hongtao Zhang et al. J Clin Invest.2007 Aug.

Abstract

Understanding the genetic origin of cancer at the molecular level has facilitated the development of novel targeted therapies. Aberrant activation of the ErbB family of receptors is implicated in many human cancers and is already the target of several anticancer therapeutics. The use of mAbs specific for the extracellular domain of ErbB receptors was the first implementation of rational targeted therapy. The cytoplasmic tyrosine kinase domain is also a preferred target for small compounds that inhibit the kinase activity of these receptors. However, current therapy has not yet been optimized, allowing for opportunities for optimization of the next generation of targeted therapy, particularly with regards to inhibiting heteromeric ErbB family receptor complexes.

PubMed Disclaimer

Figures

Figure 1
Figure 1. ErbB receptors and their ligands.
All four members of the ErbB receptor family share high homology in the extracellular domain and the kinase domain. However, ErbB3 is not kinase active. So far no ligand has been found for p185her2/neu, which has been found to be the preferred dimerization partner for other receptors. Only a few examples of receptor dimers are shown here. Ectodomain-truncated receptors also exist in some cancer cells. NRG1, neuregulin 1.
Figure 2
Figure 2. Molecules in the ErbB signaling pathways as targets for cancer therapies.
FDA-approved drugs include three mAbs targeting the extracellular domain of ErbB and three TKIs targeting the kinase domains. Trastuzumab targets p185her2/neu. Cetuximab and panitumumab target EGFR. Some TKIs (gefitinib, erlotinib) are only specific for EGFR, while lapatinib and HKI-272 also broadly inhibit other receptors in the family. Inhibitors to molecules downstream of ErbB signaling pathways, such as Src, AKT, survivin, and mTor, are also potential therapeutics for ErbB-mediated transformation. AHNP-SA, AHNP-streptavidin; scFv, single-chain variable fragment.
See this image and copyright information in PMC

References

    1. Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497. - PubMed
    1. Rowley J.D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–293. - PubMed
    1. Druker B.J., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996;2:561–566. - PubMed
    1. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001;2:127–137. - PubMed
    1. Slamon D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001;344:783–792. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full text links
American Society for Clinical Investigation full text link American Society for Clinical Investigation Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp